专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20220332807A1 IMMUNOGLOBULIN VARIABLE DOMAINS 有权
公开(公告)号：US20220332807A1
公开(公告)日：2022-10-20
申请号：US17704063
申请日：2022-03-25
申请人： Ablynx N.V. , Sanofi
发明人： Marie-Ange Buyse , Carlo Boutton
IPC分类号： C07K16/18 , C07K16/00 , C07K16/28 , C07K16/42 , C07K16/32 , C07K16/30 , C07K16/24
摘要： VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

2. 发明申请

US20220298227A9 TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS 有权
公开(公告)号：US20220298227A9
公开(公告)日：2022-09-22
申请号：US17408893
申请日：2021-08-23
申请人： Ablynx N.V.
发明人： Judith Baumeister , Marie-Paule Lucienne Armanda Bouche , Carlo Boutton , Marie-Ange Buyse , Veerle Snoeck , Stephanie Staelens , Bruno Dombrecht , Peter Schotte , Cedric Jozef Néotère Ververken , Gerald Beste , Guy Hermans , Soren Steffensen , Alexander Szyroki , Tinneke Denayer
IPC分类号： C07K16/00 , C07K16/18
摘要： This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

3. 发明授权

US11426468B2 Cysteine linked nanobody dimers 有权
公开(公告)号：US11426468B2
公开(公告)日：2022-08-30
申请号：US15536751
申请日：2015-12-18
申请人： Ablynx N.V.
发明人： Daniel Janssen , Peter Schotte , Francis Descamps , Carlo Boutton , Peter Casteels
IPC分类号： A61K47/68 , C07K16/18 , C07K16/28 , A61K51/10 , C07K16/30 , C07K16/46 , A61K39/00 , C07K1/16
摘要： The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (1ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.

4. 发明申请

US20220213215A1 POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING GLYPICAN-3 AND T CELL RECEPTOR 有权
公开(公告)号：US20220213215A1
公开(公告)日：2022-07-07
申请号：US17553908
申请日：2021-12-17
申请人： Ablynx N.V. , Sanofi
发明人： Daniel Janssen , Carlo Boutton , Evelyne Dombrecht , Bram Laukens , Paolo Meoni , Lily Pao , Jan Pype , Peter Schotte , Benedikte Serruys , Ana Paula Vintem , Diane Van Hoorick
IPC分类号： C07K16/30 , C07K16/28 , A61P35/00
摘要： The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.

5. 发明申请

US20210269514A1 IMMUNOGLOBULIN VARIABLE DOMAINS 有权
公开(公告)号：US20210269514A1
公开(公告)日：2021-09-02
申请号：US17215039
申请日：2021-03-29
申请人： Ablynx N.V.
发明人： Marie-Ange Buyse , Carlo Boutton
IPC分类号： C07K16/18 , C07K16/00 , C07K16/28 , C07K16/42 , C07K16/32 , C07K16/30 , C07K16/24
摘要： VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

6. 发明授权

US09969805B2 Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors 有权
公开(公告)号：US09969805B2
公开(公告)日：2018-05-15
申请号：US14592022
申请日：2015-01-08
申请人： Ablynx N.V.
发明人： Hilde Adi Pierrette Revets , Carlo Boutton , Hendricus Renerus Jacobus Mattheus Hoogenboom
IPC分类号： C07K16/28 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2863 , A61K39/3955 , A61K2039/505 , C07K16/3007 , C07K16/32 , C07K16/468 , C07K2317/22 , C07K2317/31 , C07K2317/32 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/64 , C07K2317/76 , C07K2317/94 , C07K2319/00
摘要： The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

7. 发明申请

US20140205597A1 TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS 审中-公开
标题翻译：涉及免疫球蛋白单个可变区域的测定中预测，检测和降低相关蛋白质干扰的技术
公开(公告)号：US20140205597A1
公开(公告)日：2014-07-24
申请号：US14138863
申请日：2013-12-23
申请人： Ablynx N.V.
发明人： Judith Baumeister , Marie-Paule Lucienne Armanda Bouche , Carlo Boutton , Marie-Ange Buyse , Veerle Snoeck , Stephanie Staelens , Bruno Dombrecht , Peter Schotte , Cedric Jozef Neotere Ververken , Gerald Beste , Guy Hermans , Soren Steffensen , Alexander Szyroki , Tinneke Denayer
IPC分类号： G01N33/68 , C07K16/18
CPC分类号： G01N33/6857 , A61K2039/505 , C07K16/18 , C07K16/2863 , C07K16/4258 , C07K2317/22 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.
摘要翻译：本发明提供并且在某些特定但非限制性方面涉及：可用于预测给定ISV是否将如本文所述受到蛋白质干扰和/或产生（特异性）信号的测定法测定（例如在ADA免疫测定中）。这样的预测测定可以例如用于测试给定的ISV是否可能具有引起这种蛋白质干扰和/或这种信号的倾向; 选择不是或不太容易发生蛋白质干扰的ISV或给出这样的信号; 作为可用于测试对ISV的某些修改（完全或部分）是否降低其引起这种干扰或这种信号的趋势的测定或测试; 和/或作为可用于指导ISV的修饰或改进的测定或测试，以便减少引起这种蛋白质干扰或信号的趋势; 修改和/或改善ISV以消除或减少其引起这种蛋白质干扰或这种信号的趋势的方法; 可以引入到ISV中的修饰，其可以去除或减少引起这种蛋白质干扰或这种信号的趋势; 已经特别选择的ISV（例如，使用本文所述的测定）具有没有或低（呃）/降低的趋势导致这种蛋白质干扰或这种信号; 修饰和/或改进的ISV，其没有或低（呃）/降低的趋势引起这种蛋白质干扰或这种信号。

8. 发明申请

US20220324951A1 GLYCOSYLATED IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS 有权
公开(公告)号：US20220324951A1
公开(公告)日：2022-10-13
申请号：US17697110
申请日：2022-03-17
申请人： Ablynx N.V.
发明人： Marie-Ange Buyse , Carlo Boutton
IPC分类号： C07K16/18
摘要： The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISV” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present. For example, the present invention relates to heavy-chain immunoglobulin variable domain, which contains a glycosylation site such that the amino acid residue at one of positions 10, 11, 12, 13, 14, 39, 40, 41, 42, 87, 89, 108, 110, 112, 113 or 114, and in particular one of positions 11, 13, 87, 89, 108, 110, 112, 113 or 114 (numbering according to Kabat) is or can be glycosylated.

9. 发明申请

US20220135657A9 IMMUNOGLOBULIN VARIABLE DOMAINS 有权
公开(公告)号：US20220135657A9
公开(公告)日：2022-05-05
申请号：US17215039
申请日：2021-03-29
申请人： Ablynx N.V.
发明人： Marie-Ange Buyse , Carlo Boutton
IPC分类号： C07K16/18 , C07K16/00 , C07K16/28 , C07K16/42 , C07K16/32 , C07K16/30 , C07K16/24
摘要： VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

10. 发明授权

US11319364B2 Immunoglobulin variable domains 有权
公开(公告)号：US11319364B2
公开(公告)日：2022-05-03
申请号：US17215163
申请日：2021-03-29
申请人： Ablynx N.V.
发明人： Marie-Ange Buyse , Carlo Boutton
IPC分类号： C07K16/24 , C07K16/28 , C07K16/42 , C07K16/32 , C07K16/30 , C07K16/18 , C07K16/00
摘要： VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which a is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式